Sex differences in K+-evoked striatal dopamine output from superfused striatal tissue fragments of reserpine-treated CD-1 mice

Journal of Neuroendocrinology

Volumn 19, Issue 9, 2007, Pages 725-731

  Ji, J ^a   Mcdermott, J L ^a   Dluzen, Dean E ^a  

^a Northeast Ohio Medical University   (United States)

Author keywords

Corpus striatum; Methamphetamine; Parkinson's disease; Sex dimorphism; Vesicular monoamine transporter 2

Indexed keywords

DOPAMINE; METHAMPHETAMINE; POTASSIUM CHANNEL; RESERPINE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; FEMALE; MALE; MOUSE; NERVE DEGENERATION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; SEX DIFFERENCE;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; FEMALE; MALE; METHAMPHETAMINE; MICE; POTASSIUM; RESERPINE; SEX FACTORS; TISSUE CULTURE TECHNIQUES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 34548557252     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2007.01581.x     Document Type: Article

References (48)

1. Becker JB, Ramirez VD. Dynamics of endogenous catecholamine release from brain fragments of male and female rats. Neuroendocrinology 1980; 31: 18-25.
2. Becker JB. Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav 1999; 64: 803-812.
3. Crowley WR, O'Donohue TL, Jacobowitz DM. Sex differences in catecholamine content in discrete brain nuclei of the rat: Effects of neonatal castration or testosterone treatment. Acta Endocrinol (Copenh) 1978; 89: 20-28.
4. Dluzen DE, Mickley KR. Gender differences in modulatory effects of tamoxifen upon the nigrostriatal dopaminergic system. Pharmacol Biochem Behav 2005; 80: 27-33.
5. Fernandez-Ruiz J, De Miguel R, Hernandez ML, Cebeira M, Ramos JA. Comparisons between brain dopaminergic neurons of juvenile and aged rats: Sex-related differences. Mech Ageing 1992; 63: 45-55.
6. McDermott JL, Liu B, Dluzen DE. Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice. Exp Neurol 1994; 125: 306-311.
7. Brooks WJ, Jarvis MF, Wagner GC. Influence of sex, age and strain of MPTP-induced neurotoxicity. Res Comm Subst Abuse 1989; 10: 181-184.
8. Miller DB, Ali SF, O'Callaghan JP, Laws SC. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann NY Acad Sci 1998; 844: 153-165.
9. Dluzen DE. Estrogen decreases corpus striatal nerotoxicity in response to 6-hydroxydopamine. Brain Res 1997; 767: 340-344.
10. Murray HE, Pillai AV, McArthur SR, Razvi N, Datla KP, Dexter DT, Gillies GE. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: Differential actions of estrogen in males and females. Neuroscience 2003; 116: 213-222.
11. Dluzen DE, McDermott JL, Anderson LI. Tamoxifen diminishes methamphetamine-induced striatal dopamine depletion in intact female and male mice. J Neuroendocrinol 2001; 13: 618-624.
12. Dluzen DE, Horstink M. Estrogen as neuroprotectant of nigrostriatal dopaminergic system: Laboratory and clinical studies. Endocrine 2003; 21: 67-75.
13. Wagner GC, Tekirian TL, Cheo CT. Sexual differences in sensitivity to methamphetamine toxicity. J Neural Transm Gen Sect 1993; 93: 67-70.
14. Yu L, Liao PC. Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice. J Neural Transm 2000; 107: 419-427.
15. Yu YL, Wagner GC. Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced nerotoxicity. J Neural Transm Parkinson's Dis Dement Sect 1994; 8: 215-221.
16. Hall JN, Broderick PM. Community networks for response to abuse outbreaks of methamphetamine and its analogs. NIDA Res Monogr 1991; 115: 109-120.
17. Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, Grigoletto F, Amaducci L, Inzitari D. Parkinson's disease and parkinsonism in a longitudinal study: Two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000; 55: 1358-1363.
18. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. Mov Disord 2000; 15: 819-825.
19. Dluzen DE, Disshon KA, McDermott JL. Estrogen as a modulator of striatal dopaminergic neurotoxicity. In: Marwah J, Tietelbaum H, eds. Recent Advances in Neurodegenerative Disorders. Scottsdale, AZ: Prominent Press, 1998: 149-192.
20. Swerdlow RH, Parker WD, Currie LJ, Bennett JP, Harrison MB, Trugman JM, Wooten GF. Gender ratio differences between Parkinson's disease patients and their affected relatives. Parkinsonism Relat Disord 2001; 7: 129-133.
21. Dluzen DE, Salvaterra TJ. Sex differences in methamphetamine-evoked striatal dopamine output are abolished following gonadectomy: comparisons with potassium-evoked output and responses in prepubertal mice. Neuroendocrinology 2005; 82: 78-86.
22. Colburn RW, Kopin IJ. Effects of reserpine and tyramine on release of norepinephrine from synaptosomes. Biochem Pharmacol 1972; 21: 733-736.
23. Imperato A, Obinu MC, Dazzi L, Gessa GL. Does dopamine exert a tonic inhibitory control on the release of striatal acetylcholine in vivo? Eur J Pharmacol 1994; 251: 271-279.
24. Kunnathur V, Shemisa K, Liu B, Salvaterra TJ, Dluzen DE. Sex differences in methamphetamine-evoked striatal dopamine of mice are reversed by nomifensine. Neurotoxicol Teratol 2006; 28: 557-562.
25. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR. Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 1997; 282: 834-838.
26. Metzger RR, Brown JM, Sandoval V, Rau KS, Elwan MA, Miller GW, Hanson GR, Fleckenstein AE. Inhibitory effect of reserpine on dopamine transporter function. Eur J Pharmacol 2002; 456: 39-43.
27. Gao X, Dluzen DE. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 2001; 103: 385-394.
28. Liu B, Dluzen DE. Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system. Synapse 2006; 60: 354-361.
29. Schuldiner S, Liu Y, Edwards RH. Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. J Biol Chem 1993; 268: 29-34.
30. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 1989; 86: 1398-1400.
31. Florin SM, Kuczenski R, Segal DS. Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: Mechanistic and behavioral considerations. J Pharmacol Exp Ther 1995; 74: 231-241.
32. Vilpoux C, Leroux-Nicollet I, Naudon L, Raisman-Vozari R, Costentin J. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain. Neuropharmacology 2000; 39: 1075-1082.
33. Bhatt SD, Dluzen DE. Dopamine transporter function differences between male and female CD-1 mice. Brain Res 2005; 1035: 188-195.
34. Rehavi M, Goldin M, Roz N, Weizman A. Regulation of rat brain vesicle monoamine transporter by chronic treatment with ovarian hormones. Brain Res Mol Brain Res 1998; 57: 31-37.
35. Le Saux M, Di Paolo T. Influence of estrogenic compounds on monoamine transporter in rat striatum. J Neuroendocrinol 2006; 18: 25-32.
36. Seiden LS, Vosmer G. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmacol Biochem Behav 1984; 21: 29-31.
37. Sulzer D, Maidment NT, Rayport S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 1993; 60: 527-535.
38. Cadet JL, Jayanthi S, Deng X. Speed kills: Cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 2003; 17: 1775-1788.
39. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: An in vitro model. J Neurosci 2001; 21: 1413-1419.
40. Xie T, McCann UD, Kim S, Yuan J, Ricaurte GA. Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: Implications for methamphetamine-induced dopaminergic neurotoxicity. J Neurosci 2000; 20: 7838-7845.
41. Fleckenstein AE, Hanson GR. Impact of psychostimulants on vesicular monoamine transporter function. Eur J Pharmacol 2003; 479: 283-289.
42. Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 2006; 319: 237-246.
43. Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, Rudnick G. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol Pharmacol 1993; 44: 1227-1231.
44. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci USA 2005; 102: 3495-3500.
45. Liu Y, Peter D, Roghani A, Schuldiner S, Prive GG, Eisenberg D, Brecha N, Edwards RH. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 1992; 70: 539-551.
46. Daniels AJ, Reinhard JF Jr. Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J Biol Chem 1988; 263: 5034-5036.
47. Moriyama Y, Amakatsu K, Futai M. Uptake of the neurotoxin, 4-methylphenylpyridinium, into chromaffin granules and synaptic vesicles: A proton gradient drives its uptake through monoamine transporter. Arch Biochem Biophys 1993; 305: 271-277.
48. Reinhard JF Jr, Diliberto EJ Jr, Viveros OH, Daniels AJ. Subcellular compartmentalisation of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci USA 1987; 84: 8160-8164.